Arbutus Biopharma (ABUS) Tops Q2 EPS by 1c

Arbutus Biopharma (NASDAQ: ABUS) reported Q2 EPS of ($0.10), $0.01 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $4.65 million versus the consensus estimate of $6.18 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• SpaceX: New Street Research sees 22% upside from proposed IPO price
• Morgan Stanley Upgrades Towa Pharmaceutical Co Ltd (4553:JP) to Overweight
• Anterix Inc. (ATEX) Tops Q4 EPS by 152c